Anti-Cancer Activity of a Novel Small Molecule Compound That Simultaneously Activates p53 and Inhibits NF-κB Signaling
Authors:
Open Access
- 13 September 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (9) , e44259
Abstract
The p53 and NF-κB pathways play important roles in diverse cellular functions, including cell growth, apoptosis, and tumorigenesis. Mutations that inactivate the p53 gene and constitutive NF-κB pathway activation are common occurrences in human cancers. Although many drugs are being developed that selectively activate p53 or inhibit NF-κB, there are few drug candidates that can do both. Simultaneous activation of p53 and inhibition of the NF-κB pathway is therefore a prime target for new cancer drug development. This study is the first report of a high-throughput approach with mass compounds that concurrently target both pathways. Using a cell-based screening assay and a library of 200,000 synthetic compounds, we identified 9 small molecules that simultaneously inhibit NF-κB and activate p53. One of these compounds, N-2, increased the expression of p53 target genes, including p21 and GADD45a. In addition, N-2 inhibited the transcriptional activity of NF-κB, concomitantly repressing interleukin-6 and monocyte chemotactic protein-1 (MCP-1) expression. When cell lines derived from a diverse range of cancers were treated in vitro with N-2, we observed increased cell death. N-2 also significantly inhibited allograft growth in murine models of melanoma and lung carcinoma. Our findings suggest that N-2 may act as a bivalent anti-cancer agent through simultaneous modulation of NF-κB and p53 activities.Keywords
This publication has 57 references indexed in Scilit:
- Stage-specific sensitivity to p53 restoration during lung cancer progressionNature, 2010
- Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cellsCancer Letters, 2010
- Awakening guardian angels: drugging the p53 pathwayNature Reviews Cancer, 2009
- p53 Attenuates Lipopolysaccharide-Induced NF-κB Activation and Acute Lung InjuryThe Journal of Immunology, 2009
- Lung CancerNew England Journal of Medicine, 2008
- Ras, PI(3)K and mTOR signalling controls tumour cell growthNature, 2006
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004
- Human Papillomavirus Type 16 E7 Binds to E2F1 and Activates E2F1-driven Transcription in a Retinoblastoma Protein-independent MannerJournal of Biological Chemistry, 2002
- Phosphorylation of human p53 by p38 kinase coordinates N‐terminal phosphorylation and apoptosis in response to UV radiationThe EMBO Journal, 1999
- CORRELATION OF ANCHORAGE-INDEPENDENT GROWTH WITH TUMORIGENICITY OF CHEMICALLY TRANSFORMED MOUSE EPIDERMAL-CELLS1978